Pharvaris announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release (XR) tablet for the prevention ...
CHAPTER-3 is a phase 3, double-blind, placebo-controlled study that evaluated orally administered deucrictibant XR tablet (40 mg, once daily) for the prevention of attacks in adolescents and adults ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results